BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zheng Y, Huang Z, Chen X, Tian Y, Tang J, Zhang Y, Zhang X, Zhou J, Mao Q, Ni B. Effects of telbivudine treatment on the circulating CD4+ T-cell subpopulations in chronic hepatitis B patients. Mediators Inflamm. 2012;2012:789859. [PMID: 22570512 DOI: 10.1155/2012/789859] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Feng H, Yin J, Han YP, Zhou XY, Chen S, Yang L, Yan JR, Zhang GX. Sustained Changes of Treg and Th17 Cells During Interferon-α Therapy in Patients with Chronic Hepatitis B. Viral Immunol 2015;28:412-7. [PMID: 26266573 DOI: 10.1089/vim.2015.0024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
2 Huang Z, Zhao Z, Zheng Y, Peng L, Lin C, Deng H, Gao Z. Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study. J Viral Hepat 2013;20:52-7. [DOI: 10.1111/jvh.12064] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
3 Tavakolpour S, Mirsafaei HS, Elkaei Behjati S, Ghasemiadl M, Akhlaghdoust M, Sali S. Toward cure chronic hepatitis B infection and hepatocellular carcinoma prevention: Lessons learned from nucleos(t)ide analogues therapy. Immunol Lett 2017;190:206-12. [PMID: 28827021 DOI: 10.1016/j.imlet.2017.08.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
4 Gong J, Liu X. Effect of HBIG combined with hepatitis B vaccine on blocking HBV transmission between mother and infant and its effect on immune cells. Exp Ther Med 2018;15:919-23. [PMID: 29399100 DOI: 10.3892/etm.2017.5474] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
5 Meng N, Gao X, Yan W, Wang M, Liu P, Lu XD, Zhang SJ, Lu YQ, Tang WX. Efficacy of telbivudine in the treatment of chronic hepatitis b and liver cirrhosis and its effect on immunological responses. J Huazhong Univ Sci Technolog Med Sci. 2015;35:230-234. [PMID: 25877357 DOI: 10.1007/s11596-015-1416-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
6 Moreno-Cubero E, Arco RTSD, Peña-Asensio J, Villalobos ES, Míquel J, Larrubia JR. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients? World J Gastroenterol 2018; 24(17): 1825-1838 [PMID: 29740199 DOI: 10.3748/wjg.v24.i17.1825] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
7 Wang HJ, Jiang YF, Wang XR, Zhang ML, Gao PJ. Elevated serum interleukin-38 level at baseline predicts virological response in telbivudine-treated patients with chronic hepatitis B. World J Gastroenterol 2016; 22(18): 4529-4537 [PMID: 27182162 DOI: 10.3748/wjg.v22.i18.4529] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
8 Liang X, Liu P, He Z, Chen X, Xiao X. The effect of maternal use of telbivudine on neonatal CD4+CD25+ regulatory T cells for the prevention of mother-to-child transmission of hepatitis B virus. Clin Res Hepatol Gastroenterol 2020;44:195-203. [PMID: 31257091 DOI: 10.1016/j.clinre.2019.06.004] [Reference Citation Analysis]
9 Zhang G, Wang W, Li S, Yang H, Zhang M, Zhang P, Wen Y, Wu A, Yang L, Zhou B, Chen X. IL6 gene allele-specific C/EBPα-binding activity affects the development of HBV infection through modulation of Th17/Treg balance. Genes Immun 2015;16:528-35. [PMID: 26447433 DOI: 10.1038/gene.2015.40] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
10 Wang J, Ma K, Han M, Guo W, Huang J, Yang D, Zhao X, Song J, Tian D, Qi J, Huang Y, Ning Q. Nucleoside analogs prevent disease progression in HBV-related acute-on-chronic liver failure: validation of the TPPM model. Hepatol Int 2014;8:64-71. [PMID: 26202407 DOI: 10.1007/s12072-013-9485-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
11 Yang Z, Tang T, Wei X, Yang S, Tian Z. Type 1 innate lymphoid cells contribute to the pathogenesis of chronic hepatitis B. Innate Immun. 2015;21:665-673. [PMID: 25977358 DOI: 10.1177/1753425915586074] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
12 Wang ML, Zhou QL, Chen EQ, Du LY, Yan LB, Bai L, He M, Tang H. Low Ratio of Treg to Th17 Cells After 36 Weeks of Telbivudine Therapy Predict HBeAg Seroconversion. Viral Immunol 2016;29:332-42. [PMID: 27104358 DOI: 10.1089/vim.2016.0007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
13 Wang Q, Zhou J, Zhang B, Tian Z, Tang J, Zheng Y, Huang Z, Tian Y, Jia Z, Tang Y, van Velkinburgh JC, Mao Q, Bian X, Ping Y, Ni B, Wu Y. Hepatitis B virus induces IL-23 production in antigen presenting cells and causes liver damage via the IL-23/IL-17 axis. PLoS Pathog 2013;9:e1003410. [PMID: 23825942 DOI: 10.1371/journal.ppat.1003410] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 5.6] [Reference Citation Analysis]
14 Ouyang Y, Fu X, Peng S, Tan D, Fu L. Plasma miR-146a predicts serological conversion of hepatitis B e-antigen (HBeAg) in chronic hepatitis B patients treated with nucleotide analogs. Ann Transl Med 2019;7:449. [PMID: 31700885 DOI: 10.21037/atm.2019.08.72] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Su QM, Ye XG. Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: A meta-analysis. World J Gastroenterol 2012; 18(43): 6290-6301 [PMID: 23180951 DOI: 10.3748/wjg.v18.i43.6290] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
16 Yu XP, Guo RY, Su ML, Ming DS, Lin CZ, Deng Y, Lin ZZ, Su ZJ. Dynamic Changes of Treg and Th17 Cells and Related Cytokines Closely Correlate With the Virological and Biochemical Response in Chronic Hepatitis B Patients Undergoing Nucleos(t)ide Analogues Treatment. Hepat Mon. 2013;13:e15332. [PMID: 24403916 DOI: 10.5812/hepatmon.15332] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
17 Li CZ, Hu JJ, Xue JY, Yin W, Liu YY, Fan WH, Xu H, Liang XS. Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B. World J Gastroenterol 2014; 20(28): 9486-9496 [PMID: 25071343 DOI: 10.3748/wjg.v20.i28.9486] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
18 Zhang Y, Wang YT, Luo JX, Hu XY, Yang F, Lin W, Liang X, Zhao BJ, Zhang S, Chen YY. Effect of WSP, a Chinese Herbal Formula, on Th17/Treg Ratio and HBeAg Seroconversion in Telbivudine-Treated HBeAg-Positive Chronic Hepatitis B Patients with High Baseline ALT Levels (20-30 Times the ULN). Evid Based Complement Alternat Med 2019;2019:7260369. [PMID: 30949222 DOI: 10.1155/2019/7260369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
19 Hao C, Wang J, Kang W, Xie Y, Zhou Y, Ma L, Peng M, Bai X, Lian J, Jia Z. Kinetics of Th17 Cytokines During Telbivudine Therapy in Patients With Chronic Hepatitis B. Viral Immunology 2013;26:336-42. [DOI: 10.1089/vim.2013.0032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]